{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:50:56Z","timestamp":1794293456841,"version":"4.9.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM). NMO is caused by a pathogenic serum IgG antibody against the water channel aquoporin 4 (AQP4) in the majority of patients. AQP4-antibody (AQP4-ab) presence is highly specific, and differentiates NMO from multiple sclerosis. It binds to AQP4 channels on astrocytes, triggering activation of the classical complement cascade, causing granulocyte, eosinophil, and lymphocyte infiltration, culminating in injury first to astrocyte, then oligodendrocytes followed by demyelination and neuronal loss. NMO spectrum disorder (NMOSD) has recently been defined and stratified based on AQP4-ab serology status. Most NMOSD patients experience severe relapses leading to permanent neurologic disability, making suppression of relapse frequency and severity, the primary objective in disease management. The most common treatments used for relapses are steroids and plasma exchange.<\/jats:p>\n                  <jats:p>\n                    Currently, long-term NMOSD relapse prevention includes off-label use of immunosuppressants, particularly rituximab. In the last 2 years however, three pivotal clinical trials have expanded the spectrum of drugs available for NMOSD patients. Phase III studies have shown significant relapse reduction compared to placebo in AQP4-ab-positive patients treated with satralizumab, an interleukin-6 receptor (IL-6R) inhibitor, inebilizumab, an antibody against CD19\n                    <jats:sup>+<\/jats:sup>\n                    B cells; and eculizumab, an antibody blocking the C5 component of complement. In light of the new evidence on NMOSD pathophysiology and of preliminary results from ongoing trials with new drugs, we present this descriptive review, highlighting promising treatment modalities as well as auspicious preclinical and clinical studies.\n                  <\/jats:p>","DOI":"10.1186\/s12974-021-02249-1","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:04:58Z","timestamp":1631775898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":336,"title":["Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5726","authenticated-orcid":false,"given":"Edgar","family":"Carnero Contentti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"issue":"2","key":"2249_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137\u2013145.3. https:\/\/doi.org\/10.1136\/jnnp-2016-313300.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"2249_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s004150200020","volume":"249","author":"I Miyazawa","year":"2002","unstructured":"Miyazawa I, Fujihara K, Itoyama Y. Eug\u00e8ne Devic (1858-1930). J Neurol. 2002;249(3):351\u20132.","journal-title":"J Neurol."},{"issue":"5","key":"2249_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107\u201314. https:\/\/doi.org\/10.1212\/WNL.53.5.1107.","journal-title":"Neurology."},{"key":"2249_CR4","doi-asserted-by":"crossref","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.","DOI":"10.1016\/S0140-6736(04)17551-X"},{"issue":"4","key":"2249_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med."},{"issue":"10","key":"2249_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000216139.44259.74.","journal-title":"Neurology."},{"issue":"9","key":"2249_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315. https:\/\/doi.org\/10.1016\/S1474-4422(07)70216-8.","journal-title":"Lancet Neurol."},{"issue":"9","key":"2249_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458508096878","volume":"14","author":"DH Miller","year":"2008","unstructured":"Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14(9):1157\u201374.","journal-title":"Mult Scler."},{"key":"2249_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.","journal-title":"J Neuroinflammation."},{"issue":"2","key":"2249_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology."},{"issue":"2","key":"2249_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol."},{"issue":"1","key":"2249_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2.","journal-title":"J Neuroinflammation."},{"issue":"7","key":"2249_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med."},{"issue":"5","key":"2249_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R H\u00f6ftberger","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875\u201392. https:\/\/doi.org\/10.1007\/s00401-020-02132-y.","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2249_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474\u201381.","journal-title":"Neurology."},{"issue":"2","key":"2249_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89\u2013102.","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"2249_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310\u201323.","journal-title":"Brain."},{"key":"2249_CR18","doi-asserted-by":"publisher","first-page":"102428","DOI":"10.1016\/j.msard.2020.102428","volume":"45","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020;45:102428.","journal-title":"Mult Scler Relat Disord."},{"issue":"22","key":"2249_CR19","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1901747.","journal-title":"N Engl J Med."},{"issue":"5","key":"2249_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol."},{"issue":"10206","key":"2249_CR21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet."},{"issue":"26","key":"2249_CR22","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1073\/pnas.91.26.13052","volume":"91","author":"JS Jung","year":"1994","unstructured":"Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A. 1994;91(26):13052\u20136. https:\/\/doi.org\/10.1073\/pnas.91.26.13052.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2249_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245\u201350.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"18","key":"2249_CR24","doi-asserted-by":"publisher","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","volume":"286","author":"JM Crane","year":"2011","unstructured":"Crane JM, Lam C, Rossi A, et al. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays. J Biol Chem. 2011;286(18):16516\u201324.","journal-title":"J Biol Chem."},{"issue":"6","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(12)70133-3.","journal-title":"Lancet Neurol."},{"issue":"17","key":"2249_CR26","doi-asserted-by":"publisher","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem. 2012;287(17):13829\u201339.","journal-title":"J Biol Chem."},{"issue":"1","key":"2249_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","volume":"7","author":"BF Popescu","year":"2012","unstructured":"Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7(1):185\u2013217. https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132443.","journal-title":"Annu Rev Pathol."},{"issue":"24","key":"2249_CR28","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69(24):2221\u201331.","journal-title":"Neurology."},{"issue":"Pt 7","key":"2249_CR29","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u201361. https:\/\/doi.org\/10.1093\/brain\/awf151.","journal-title":"Brain."},{"issue":"Pt 11","key":"2249_CR30","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(Pt 11):3072\u201380.","journal-title":"Brain."},{"issue":"1-2","key":"2249_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jns.2012.06.002","volume":"320","author":"S Jarius","year":"2012","unstructured":"Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012;320(1-2):32\u20137. https:\/\/doi.org\/10.1016\/j.jns.2012.06.002.","journal-title":"J Neurol Sci."},{"issue":"5","key":"2249_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458511424590","volume":"18","author":"W Kim","year":"2012","unstructured":"Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler. 2012;18(5):578\u201386. https:\/\/doi.org\/10.1177\/1352458511424590.","journal-title":"Mult Scler."},{"issue":"1","key":"2249_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14. https:\/\/doi.org\/10.1186\/1742-2094-9-14.","journal-title":"J Neuroinflammation."},{"issue":"3","key":"2249_CR34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566\u20139.","journal-title":"Ann Neurol."},{"issue":"3","key":"2249_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390\u20136.","journal-title":"Arch Neurol."},{"issue":"9","key":"2249_CR36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","volume":"70","author":"M Matiello","year":"2013","unstructured":"Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol. 2013;70(9):1118\u201325.","journal-title":"JAMA Neurol."},{"issue":"1","key":"2249_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","volume":"9","author":"SH Kim","year":"2013","unstructured":"Kim SH, Kim W, Huh SY, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol. 2013;9(1):36\u201342.","journal-title":"J Clin Neurol."},{"key":"2249_CR38","doi-asserted-by":"crossref","unstructured":"Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;(4):487\u201392.","DOI":"10.1177\/1352458508100837"},{"issue":"11","key":"2249_CR39","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412\u201320.","journal-title":"Arch Neurol."},{"issue":"4","key":"2249_CR40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol."},{"issue":"11","key":"2249_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027412","volume":"6","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One. 2011;6(11):e27412.","journal-title":"PLoS One."},{"key":"2249_CR42","doi-asserted-by":"crossref","unstructured":"Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in na\u00efve rats by intracerebral administration of NMO-IgG. Acta Neuropathol Comm .2014; 2:48","DOI":"10.1186\/2051-5960-2-48"},{"issue":"12","key":"2249_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","volume":"72","author":"EC Klawiter","year":"2009","unstructured":"Klawiter EC, Alvarez E 3rd, Xu J, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 2009;72(12):1101\u20133.","journal-title":"Neurology."},{"issue":"9","key":"2249_CR44","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701\u20136. https:\/\/doi.org\/10.1073\/pnas.1017385108.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2249_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617\u201329.","journal-title":"Ann Neurol."},{"issue":"2","key":"2249_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/jnc.14339","volume":"146","author":"M Lindner","year":"2018","unstructured":"Lindner M, Klotz L, Wiendl H. Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity. J Neurochem. 2018;146(2):122\u201332.","journal-title":"J Neurochem."},{"issue":"2","key":"2249_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1006\/exnr.1993.1059","volume":"120","author":"RD Broadwell","year":"1993","unstructured":"Broadwell RD, Sofroniew MV. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol. 1993;120(2):245\u201363. https:\/\/doi.org\/10.1006\/exnr.1993.1059.","journal-title":"Exp Neurol."},{"issue":"3","key":"2249_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e104.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"2249_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000919","volume":"8","author":"J Graf","year":"2020","unstructured":"Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. Neurol Neuroimmunol Neuroinflamm. 2020;8(1):e919. https:\/\/doi.org\/10.1212\/NXI.0000000000000919.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"2249_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083036","volume":"8","author":"N Chihara","year":"2013","unstructured":"Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, Kishida H, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One. 2013;8(12):e83036. https:\/\/doi.org\/10.1371\/journal.pone.0083036.","journal-title":"PLoS One."},{"issue":"12","key":"2249_CR51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/1352458510380416","volume":"16","author":"A Vaknin-Dembinsky","year":"2010","unstructured":"Vaknin-Dembinsky A, Brill L, Orpaz N, et al. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler. 2010;16(12):1453\u20137.","journal-title":"Mult Scler."},{"issue":"9","key":"2249_CR52","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","volume":"89","author":"K Kaneko","year":"2018","unstructured":"Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018;89(9):927\u201336. https:\/\/doi.org\/10.1136\/jnnp-2018-317969.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"13","key":"2249_CR53","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1084\/jem.20130699","volume":"210","author":"N Molnarfi","year":"2013","unstructured":"Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210(13):2921\u201337.","journal-title":"J Exp Med."},{"issue":"2","key":"2249_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2010.07.015","volume":"33","author":"EK Deenick","year":"2010","unstructured":"Deenick EK, Chan A, Ma CS, Gatto D, Schwartzberg PL, Brink R, et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity. 2010;33(2):241\u201353. https:\/\/doi.org\/10.1016\/j.immuni.2010.07.015.","journal-title":"Immunity."},{"issue":"5","key":"2249_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841","volume":"7","author":"K Fujihara","year":"2020","unstructured":"Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"2249_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1352458512454771","volume":"19","author":"C Quan","year":"2013","unstructured":"Quan C, Yu H, Qiao J, et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler. 2013;19(3):289\u201398.","journal-title":"Mult Scler."},{"issue":"1","key":"2249_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.23651","volume":"72","author":"M Varrin-Doyer","year":"2012","unstructured":"Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72(1):53\u201364.","journal-title":"Ann Neurol."},{"issue":"5","key":"2249_CR58","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630\u201343. https:\/\/doi.org\/10.1002\/ana.21837.","journal-title":"Ann Neurol."},{"issue":"1","key":"2249_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1352458509350741","volume":"16","author":"DG Brum","year":"2010","unstructured":"Brum DG, Barreira AA, dos Santos AC, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler. 2010;16(1):21\u20139. https:\/\/doi.org\/10.1177\/1352458509350741.","journal-title":"Mult Scler."},{"issue":"1","key":"2249_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1352458510382810","volume":"17","author":"R Deschamps","year":"2011","unstructured":"Deschamps R, Paturel L, Jeannin S, et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult Scler. 2011;17(1):24\u201331.","journal-title":"Mult Scler."},{"issue":"1","key":"2249_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","volume":"33","author":"UC Linhares","year":"2013","unstructured":"Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013;33(1):179\u201389.","journal-title":"J Clin Immunol."},{"issue":"10","key":"2249_CR62","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","volume":"13","author":"H Kebir","year":"2007","unstructured":"Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173\u20135.","journal-title":"Nat Med."},{"issue":"47","key":"2249_CR63","doi-asserted-by":"publisher","first-page":"18460","DOI":"10.1073\/pnas.0809850105","volume":"105","author":"T Korn","year":"2008","unstructured":"Korn T, Mitsdoerffer M, Croxford AL, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105(47):18460\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"2249_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729\u201340.","journal-title":"Nat Rev Immunol."},{"issue":"8","key":"2249_CR65","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","volume":"181","author":"T Vincent","year":"2008","unstructured":"Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008;181(8):5730\u20137.","journal-title":"J Immunol."},{"issue":"1-2","key":"2249_CR66","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1-2):82\u201390.","journal-title":"J Neurol Sci."},{"issue":"6","key":"2249_CR67","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol. 2012;123(6):861\u201372. https:\/\/doi.org\/10.1007\/s00401-012-0986-4.","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2249_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","volume":"134","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Yao X, Su T, et al. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017;134(1):35\u201344.","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2249_CR69","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","volume":"15","author":"T Duan","year":"2018","unstructured":"Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2018;15(1):294.","journal-title":"J Neuroinflammation."},{"issue":"11","key":"2249_CR70","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205(11):2473\u201381.","journal-title":"J Exp Med."},{"issue":"1","key":"2249_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83\u201397.","journal-title":"Brain Pathol."},{"issue":"5","key":"2249_CR72","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/glia.22635","volume":"62","author":"CL Howe","year":"2014","unstructured":"Howe CL, Kaptzan T, Maga\u00f1a SM, et al. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia. 2014;62(5):692\u2013708.","journal-title":"Glia."},{"issue":"8","key":"2249_CR73","first-page":"4025","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen T, Lennon VA, Liu YU, et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest. 2020;130(8):4025\u201338.","journal-title":"J Clin Invest."},{"key":"2249_CR74","doi-asserted-by":"crossref","unstructured":"Dejanovic B, Huntley MA, De Mazi\u00e8re A, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;100(6):1322-1336.e7.","DOI":"10.1016\/j.neuron.2018.10.014"},{"issue":"6","key":"2249_CR75","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1523\/JNEUROSCI.5249-09.2010","volume":"30","author":"VS Ten","year":"2010","unstructured":"Ten VS, Yao J, Ratner V, et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci. 2010;30(6):2077\u201387.","journal-title":"J Neurosci."},{"issue":"5","key":"2249_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141694","volume":"131","author":"A Winkler","year":"2021","unstructured":"Winkler A, Wrzos C, Haberl M, Weil MT, Gao M, M\u00f6bius W, et al. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. J Clin Invest. 2021;131(5):e141694. https:\/\/doi.org\/10.1172\/JCI141694.","journal-title":"J Clin Invest."},{"issue":"4","key":"2249_CR77","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1352458512440060","volume":"18","author":"K Herges","year":"2012","unstructured":"Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012;18(4):398\u2013408. https:\/\/doi.org\/10.1177\/1352458512440060.","journal-title":"Mult Scler."},{"issue":"3","key":"2249_CR78","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71(3):323\u201333. https:\/\/doi.org\/10.1002\/ana.22686.","journal-title":"Ann Neurol."},{"issue":"25","key":"2249_CR79","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","volume":"289","author":"KR Acharya","year":"2014","unstructured":"Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014;289(25):17406\u201315.","journal-title":"J Biol Chem."},{"key":"2249_CR80","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391\u2013401.","journal-title":"Lancet Neurol."},{"key":"2249_CR81","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.msard.2019.101506","volume":"38","author":"T Songthammawat","year":"2019","unstructured":"Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2019;38:101506. https:\/\/doi.org\/10.1016\/j.msard.2019.101506.","journal-title":"Mult Scler Relat Disord."},{"key":"2249_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22:185\u201392.","journal-title":"Mult Scler."},{"issue":"2","key":"2249_CR83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206\u201316. https:\/\/doi.org\/10.1002\/ana.24554.","journal-title":"Ann Neurol."},{"issue":"4","key":"2249_CR84","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"2249_CR85","doi-asserted-by":"crossref","unstructured":"Kleiter I, Gahlen A, Borisow N, et al; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504.","DOI":"10.1212\/NXI.0000000000000504"},{"issue":"4","key":"2249_CR86","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, Merle H, Ferg\u00e9 JL, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346\u201351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"2249_CR87","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501\u20134. https:\/\/doi.org\/10.1177\/1352458513495938.","journal-title":"Mult Scler."},{"issue":"31","key":"2249_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21310","volume":"21","author":"M Absoud","year":"2017","unstructured":"Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, et al. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technol Assess. 2017;21(31):1\u201350. https:\/\/doi.org\/10.3310\/hta21310.","journal-title":"Health Technol Assess."},{"key":"2249_CR89","doi-asserted-by":"publisher","first-page":"102325","DOI":"10.1016\/j.msard.2020.102325","volume":"44","author":"X Li","year":"2020","unstructured":"Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020;44:102325. https:\/\/doi.org\/10.1016\/j.msard.2020.102325.","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"2249_CR90","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/cen3.12239","volume":"6","author":"MA Mealy","year":"2015","unstructured":"Mealy MA, Shin K, John G, Levy M. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6(4):413\u20138.","journal-title":"Clin Exp Neuroimmunol."},{"issue":"3","key":"2249_CR91","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420\u20139.","journal-title":"Mult Scler."},{"key":"2249_CR92","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015944","volume":"98","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against cd20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine. 2019;98:e15944.","journal-title":"Medicine"},{"issue":"8","key":"2249_CR93","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/1352458518776584","volume":"25","author":"DB Bichuetti","year":"2019","unstructured":"Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler. 2019;25(8):1150\u201361.","journal-title":"Mult Scler."},{"issue":"9","key":"2249_CR94","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003\u20139.","journal-title":"J Neurol."},{"key":"2249_CR95","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533\u201340.","journal-title":"Mult Scler."},{"key":"2249_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","volume":"33","author":"AI Espiritu","year":"2019","unstructured":"Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22\u201332.","journal-title":"Mult Scler Relat Disord."},{"issue":"10","key":"2249_CR97","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377\u201384. https:\/\/doi.org\/10.1177\/1352458516678474.","journal-title":"Mult Scler."},{"key":"2249_CR98","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"SY Huh","year":"2014","unstructured":"Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372\u20138.","journal-title":"JAMA Neurol."},{"issue":"1","key":"2249_CR99","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1038\/s41598-020-73882-8","volume":"10","author":"S Songwisit","year":"2020","unstructured":"Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727. https:\/\/doi.org\/10.1038\/s41598-020-73882-8.","journal-title":"Sci Rep."},{"issue":"1","key":"2249_CR100","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019;19(1):36. https:\/\/doi.org\/10.1186\/s12883-019-1261-2.","journal-title":"BMC Neurol."},{"key":"2249_CR101","doi-asserted-by":"crossref","unstructured":"Ciron J, Audoin B, Bourre B, et al; NOMADMUS group, under the aegis of OFSEP, SFSEP. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174(4):255-264.","DOI":"10.1016\/j.neurol.2017.11.005"},{"issue":"11","key":"2249_CR102","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of Rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342\u20138.","journal-title":"JAMA Neurol."},{"key":"2249_CR103","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324\u201330.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2249_CR104","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329\u201339.","journal-title":"Mult Scler."},{"key":"2249_CR105","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88:639\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"2249_CR106","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310\u20135. https:\/\/doi.org\/10.1212\/WNL.0b013e3182152881.","journal-title":"Neurology."},{"issue":"7","key":"2249_CR107","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","volume":"72","author":"M Ringelstein","year":"2015","unstructured":"Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, St\u00f6gbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0533.","journal-title":"JAMA Neurol."},{"issue":"15","key":"2249_CR108","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302\u20136. https:\/\/doi.org\/10.1212\/WNL.0000000000000317.","journal-title":"Neurology."},{"key":"2249_CR109","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","volume":"39","author":"I Lotan","year":"2019","unstructured":"Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;39:101920.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"2249_CR110","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/archneurol.2012.545","volume":"69","author":"DB Bichuetti","year":"2012","unstructured":"Bichuetti DB, Oliveira EM, Boulos Fde C, Gabbai AA. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol. 2012;69(7):938\u20139.","journal-title":"Arch Neurol."},{"issue":"1","key":"2249_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol."},{"issue":"27","key":"2249_CR112","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"3","key":"2249_CR113","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjh.16711","volume":"191","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Brodsky RA, Ortiz S, Risitano AM, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020;191(3):476\u201385.","journal-title":"Br J Haematol."},{"issue":"8","key":"2249_CR114","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang C, Tian DC, Yang CS, et al. Safety and efficacy of Bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74(8):1010\u20132.","journal-title":"JAMA Neurol."},{"issue":"2","key":"2249_CR115","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000441","volume":"5","author":"I Katz Sand","year":"2018","unstructured":"Katz Sand I, Fabian MT, Telford R, Kraus TA, Chehade M, Masilamani M, et al. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018;5(2):e441. https:\/\/doi.org\/10.1212\/NXI.0000000000000441.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"2249_CR116","doi-asserted-by":"crossref","unstructured":"Liossis SN, Staveri C. What's new in the treatment of systemic lupus erythematosus. Front Med (Lausanne). 2021;8:655100.","DOI":"10.3389\/fmed.2021.655100"},{"issue":"18","key":"2249_CR117","doi-asserted-by":"publisher","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","volume":"93","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732\u201341. https:\/\/doi.org\/10.1212\/WNL.0000000000008394.","journal-title":"Neurology."},{"issue":"10","key":"2249_CR118","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41409-020-0810-z","volume":"55","author":"P Zhang","year":"2020","unstructured":"Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. Bone Marrow Transplant. 2020;55(10):1928\u201334.","journal-title":"Bone Marrow Transplant."},{"key":"2249_CR119","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.neuropharm.2019.107827","volume":"162","author":"T Duan","year":"2020","unstructured":"Duan T, Tradtrantip L, Phuan PW, et al. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020;162:107827.","journal-title":"Neuropharmacology."},{"issue":"6","key":"2249_CR120","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000288","volume":"3","author":"V Davoudi","year":"2016","unstructured":"Davoudi V, Keyhanian K, Bove RM, Chitnis T. Immunology of neuromyelitis optica during pregnancy. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e288.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"22","key":"2249_CR121","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","volume":"89","author":"EC Klawiter","year":"2017","unstructured":"Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;89(22):2238\u201344. https:\/\/doi.org\/10.1212\/WNL.0000000000004681.","journal-title":"Neurology."},{"key":"2249_CR122","doi-asserted-by":"crossref","unstructured":"Collongues N, Alves Do Rego C, Bourre B, Biotti D, Marignier R, da Silva AM, Santos E, Maillart E, Papeix C, Palace J, Leite MIS, De Seze J. Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder. Neurology. 2021;96(15):e2006-e2015.","DOI":"10.1212\/WNL.0000000000011744"},{"issue":"3","key":"2249_CR123","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13167-018-0143-9","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA J. 2018;9(3):249\u201356.","journal-title":"EPMA J."},{"issue":"3","key":"2249_CR124","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16(3):154\u201370.","journal-title":"Nat Rev Neurol."},{"issue":"14","key":"2249_CR125","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/1352458517740215","volume":"23","author":"E Shosha","year":"2017","unstructured":"Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Mult Scler. 2017;23(14):1808\u201317.","journal-title":"Mult Scler."},{"issue":"3","key":"2249_CR126","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","volume":"86","author":"T Chitnis","year":"2016","unstructured":"Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86(3):245\u201352.","journal-title":"Neurology."},{"key":"2249_CR127","doi-asserted-by":"crossref","unstructured":"Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr. 2020;8:339.","DOI":"10.3389\/fped.2020.00339"},{"issue":"1","key":"2249_CR128","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00415-015-7952-8","volume":"263","author":"M Jury\u0144czyk","year":"2016","unstructured":"Jury\u0144czyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO\/MS overlap syndromes. J Neurol. 2016;263(1):140\u20139.","journal-title":"J Neurol."},{"key":"2249_CR129","doi-asserted-by":"publisher","unstructured":"Kim SH, Jang H, Park NY, Kim Y, Kim SY, Lee MY, Hyun JW, Kim HJ. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):e947. doi: https:\/\/doi.org\/10.1212\/NXI.0000000000000947. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2021;8(4): PMID: 33622675; PMCID: PMC7903808.","DOI":"10.1212\/NXI.0000000000000947"},{"issue":"5","key":"2249_CR130","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000276","volume":"3","author":"L Steinman","year":"2016","unstructured":"Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e276.","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02249-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T06:14:09Z","timestamp":1673244849000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02249-1","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Edgar Carnero Contentti has received reimbursement for developing educational presentations, educational and research grants, consultation fees, and\/or travel stipends from Biogen, Bayer, Genzyme, Merck, Novartis, Roche, Raffo, and Teva.\u00a0ECC\u00a0has also received grants from LACTRIMS and\u00a0Guthy-Jackson Charitable Foundation. Jorge Correale is a board member of Merck-Serono Argentina, Novartis Argentina, Genzyme LATAM, Genzyme global, Biogen-Idec LATAM and Merck-Serono LATAM. He is part of the Steering Committee for the clinical trials of Ofatumumab (Novartis Global). JC has received reimbursement for developing educational presentations for Merck-Serono Argentina, Merck-Serono LATAM, Biogen-Idec Argentina, Genzyme Argentina, Novartis Argentina, Novartis LATAM, Novartis Global and Roche Argentina, as well as professional travel\/accommodation stipends.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}